Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of LY4100511 Formulations With and Without Rabeprazole in Healthy Participants
NCT06916143Phase 1Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2025
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of simepdekinra (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Curve from 0 to Infinity, Maximum Concentration and 1 more. Started Apr 2025; status: terminated.
02
Drugs
simepdekinra
Beyond the preview
Go deeper on NCT06916143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06916143.